Synklino will join BII’s Creation House Programme

Spinout Synklino is among the three companies that will join the next session of BII’s Creation House programme. The programme runs for up to 18 months and sets the best framework for the companies to mature, attract funding and, ultimately, have a prototype or lead candidate.

Biotech company Synklino ApS is among the three companies that have been accepted in the latest session of BII’s Creation House Programme. Synklino is a spinout from 2017 with IP from both Technical University of Denmark and University of Copenhagen.

“Patients are infected when they are recovering from the tough procedure a transplant is. It causes increased morbidity, 30 percent longer hospitalization and it raises mortality rates”

Thomas N. Kledal, Synklino

The company aims to provide new treatment options for patients who have had a transplant. Their lead drug candidate, SYNx, is a highly effective, potent, and fast-acting CMV-specific immunotoxin with the unique ability to kill both lytic and latently infected cells, hence the potential to prevent CMV infection and disease in transplant recipients

“Patients are infected when they are recovering from the tough procedure a transplant is. It causes increased morbidity, 30 percent longer hospitalization and it raises mortality rates”, explains Thomas N. Kledal, CEO and Founder of Synklino.

With Synklino’s technology, transplant patients will increase their chance for survival and for a successful transplantation outcome. Importantly, patients will recover faster from transplantation and be less likely to be re-hospitalized. Hence the technology will benefit both patients and hospitals. The treatment will take no longer than 2 weeks – as opposed to the 100 days that is currently the best option. SYNx will target only infected cells and leave healthy cells unharmed for the wellbeing of the patient.

Initially, SYNx will be developed for patients undergoing stem cell transplantation or organ transplantation, preventing late onset CMV disease currently affecting more than 30% of the patients. Late Onset CMV causes suboptimal transplantation outcome, leading to increased morbidity, prolonged hospitalization and raised mortality rates.

“The environment at BII is equally important for us in order to move forward and we expect to attract more funding to get started on our GMP work and toxicology work in the coming 18 months”, says Thomas N. Kledal.

Creation House Programme

As a part of BII’s Creation House Programme companies have an ideal opportunity to accelerate early-stage technical and commercial validation and increase the scientific maturity to attract funding that can bring new solutions and innovative products to the market.

The Creation House Programme supports life science start-ups with technical proof of concept and a solid business plan. The aim is to accelerate the development of new products or applications with the goal of bringing new discoveries within biomedicine, medtech, industrial and biotechnology.

/Public Release. View in full here.